Sintilimab (IBI308) in Combination With Chidamide and Azacitidine in Refractory or Relapsed PTCL
Last updated on July 2021Recruitment
- Recruitment Status
- Not yet recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Peripheral T Cell Lymphoma
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 80 years
- Gender
- Both males and females
Description
PRIMARY OBJECTIVES: To determine the objective response rate (ORR). SECONDARY OBJECTIVES: To determine the complete response rate (CRR). To determine the duration of response (DOR). To determine the progression free survival (PFS). To determine the overall survival (OS). To determine the safety. EXP...
PRIMARY OBJECTIVES: To determine the objective response rate (ORR). SECONDARY OBJECTIVES: To determine the complete response rate (CRR). To determine the duration of response (DOR). To determine the progression free survival (PFS). To determine the overall survival (OS). To determine the safety. EXPLORATORY OBJECTIVES: Assess the correlation between the expression of PD-L1, CD4, CD8, CD68 in tumor microenvironment and the efficacy of combined therapy in relapsed or refractory peripheral T-cell lymphoma.
Tracking Information
- NCT #
- NCT04052659
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Yuqin Song, Doctor Cancer Hospital of Beijing University
Get Well Soon